MCID: ACN019
MIFTS: 40

Acanthamoeba Keratitis

Categories: Eye diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Acanthamoeba Keratitis

MalaCards integrated aliases for Acanthamoeba Keratitis:

Name: Acanthamoeba Keratitis 53 59 17 72

Characteristics:

Orphanet epidemiological data:

59
acanthamoeba keratitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

MESH via Orphanet 45 D015823
ICD10 via Orphanet 34 B60.1+ H19.2*
UMLS via Orphanet 73 C0000880
Orphanet 59 ORPHA67043
UMLS 72 C0000880

Summaries for Acanthamoeba Keratitis

MalaCards based summary : Acanthamoeba Keratitis is related to retinal artery occlusion and granulomatous amebic encephalitis. An important gene associated with Acanthamoeba Keratitis is APOH (Apolipoprotein H), and among its related pathways/superpathways is Complement and coagulation cascades. The drugs Polihexanide and Dibrompropamidine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are photophobia and ocular pain

Wikipedia : 75 Acanthamoeba keratitis is a rare disease in which amoebae invade the cornea of the eye, and affects... more...

Related Diseases for Acanthamoeba Keratitis

Diseases related to Acanthamoeba Keratitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 retinal artery occlusion 30.0 F5 APOH
2 granulomatous amebic encephalitis 11.5
3 keratitis, hereditary 11.4
4 herpes simplex 10.7
5 fungal keratitis 10.7
6 corneal ulcer 10.6
7 corneal disease 10.6
8 scleritis 10.5
9 cataract 10.5
10 uveitis 10.5
11 stromal keratitis 10.5
12 hypopyon 10.4
13 corneal edema 10.4
14 mature cataract 10.4
15 anterior uveitis 10.4
16 corneal neovascularization 10.4
17 neuritis 10.4
18 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
19 corneal abscess 10.4
20 myopia 10.4
21 eye disease 10.4
22 yemenite deaf-blind hypopigmentation syndrome 10.3
23 herpes simplex virus keratitis 10.3
24 endophthalmitis 10.3
25 conjunctivitis 10.3
26 dacryoadenitis 10.3
27 keratoconus 10.3
28 superficial keratitis 10.3
29 keratopathy 10.3
30 keratoconjunctivitis 10.3
31 infective keratitis 10.3
32 dry eye syndrome 10.2
33 punctate epithelial keratoconjunctivitis 10.2
34 cholera 10.2
35 chorioretinitis 10.2
36 iridocyclitis 10.2
37 may-thurner syndrome 10.1 F5 APOH
38 spinal cord infarction 10.1 F5 APOH
39 sudden sensorineural hearing loss 10.1 F5 APOH
40 cerebral sinovenous thrombosis 10.1 F5 APOH
41 thrombosis 10.0 F5 APOH
42 pregnancy loss, recurrent 1 10.0 F5 APOH
43 prothrombin deficiency, congenital 10.0 F5 APOH
44 ischemic colitis 10.0 F5 APOH
45 catastrophic antiphospholipid syndrome 10.0 F5 APOH
46 antiphospholipid syndrome 10.0 F5 APOH
47 thrombophlebitis 10.0 F5 APOH
48 retinal vascular occlusion 10.0 F5 APOH
49 autoimmune disease 10.0
50 neutrophil migration 10.0

Graphical network of the top 20 diseases related to Acanthamoeba Keratitis:



Diseases related to Acanthamoeba Keratitis

Symptoms & Phenotypes for Acanthamoeba Keratitis

Human phenotypes related to Acanthamoeba Keratitis:

59 32 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 photophobia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000613
2 ocular pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0200026
3 punctate opacification of the cornea 59 32 hallmark (90%) Very frequent (99-80%) HP:0007856
4 cataract 59 32 frequent (33%) Frequent (79-30%) HP:0000518
5 decreased corneal sensation 59 32 frequent (33%) Frequent (79-30%) HP:0012155
6 anterior uveitis 59 32 frequent (33%) Frequent (79-30%) HP:0012122
7 corneal perforation 59 32 frequent (33%) Frequent (79-30%) HP:0100583
8 scleritis 59 32 frequent (33%) Frequent (79-30%) HP:0100532
9 iris atrophy 59 32 frequent (33%) Frequent (79-30%) HP:0001089
10 abnormal posterior eye segment morphology 32 frequent (33%) HP:0004329
11 corneal stromal edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0012040
12 corneal ulceration 59 32 occasional (7.5%) Occasional (29-5%) HP:0012804
13 abnormal anterior chamber morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0000593
14 abnormality of the cornea 59 Very frequent (99-80%)
15 abnormality of corneal epithelium 59 Very frequent (99-80%)
16 abnormality of the posterior segment of the globe 59 Frequent (79-30%)

Drugs & Therapeutics for Acanthamoeba Keratitis

Drugs for Acanthamoeba Keratitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Polihexanide Approved, Investigational Phase 3 28757-47-3
2 Dibrompropamidine Experimental Phase 3 496-00-4
3
Propamidine Experimental, Investigational Phase 3 104-32-5
4 Ophthalmic Solutions Phase 3
5 Disinfectants Phase 3
6 Antiparasitic Agents Phase 3
7 Anti-Infective Agents, Local Phase 3
8 Pharmaceutical Solutions Phase 3
9 Antiprotozoal Agents Phase 3
10 Biguanides Phase 3
11 Anti-Infective Agents Phase 3
12 Hypoglycemic Agents Phase 3
13
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
14
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
15
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
16
Povidone Approved Phase 2 9003-39-8
17
Povidone-iodine Approved Phase 2 25655-41-8
18
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
19
Iodine Approved, Investigational Phase 2 7553-56-2 807
20
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
21 Gastrointestinal Agents Phase 2
22 Micronutrients Phase 2
23 Antiemetics Phase 2
24 Neuroprotective Agents Phase 2
25 Lubricant Eye Drops Phase 2
26 Anti-Inflammatory Agents Phase 2
27 Prednisolone acetate Phase 2
28 Chlorhexidine gluconate Phase 2
29 glucocorticoids Phase 2
30 Hormones Phase 2
31 Peripheral Nervous System Agents Phase 2
32 Methylprednisolone Acetate Phase 2
33 Protective Agents Phase 2
34 Plasma Substitutes Phase 2
35 Antineoplastic Agents, Hormonal Phase 2
36 Nutrients Phase 2
37 Trace Elements Phase 2
38 Hormone Antagonists Phase 2
39 Dermatologic Agents Phase 2
40 cadexomer iodine Phase 2
41 Autonomic Agents Phase 2
42 Blood Substitutes Phase 2
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
44
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
45
Tacrolimus Approved, Investigational 104987-11-3 445643 439492 6473866
46
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
47
Tobramycin Approved, Investigational 32986-56-4 36294 5496
48 Tobramycin, Dexamethasone Drug Combination
49 Immunologic Factors
50 Anti-Bacterial Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis Recruiting NCT03274895 Phase 3 PHMB 0.08%;Propamidine 0.1%;placebo;PHMB 0.02%
2 Parasitic Ulcer Treatment Trial Pilot Recruiting NCT03484507 Phase 2 Chlorhexidine;Povidone-Iodine;Prednisolone Sodium Phosphate;Hydroxypropyl Methylcellulose;Prednisolone Sodium Phosphate;Hydroxypropyl Methylcellulose
3 Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects Completed NCT02506257 Phase 1 0.04% PHMB;0.06% PHMB;0.08% PHMB;PHMB Vehicle
4 Retrospective Study of the in Vivo Confocal Microscopic Findings and the Treatment Outcome of Acanthamoebic Keratitis Unknown status NCT02763605
5 Prospective Study of Deep Anterior Lamellar Keratoplasty Using Acellular Porcine Cornea Recruiting NCT03105466 Tacrolimus eye drops;Tobradex eyedrops
6 Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists Recruiting NCT03987178
7 Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures - a Pilot Study Enrolling by invitation NCT03461978

Search NIH Clinical Center for Acanthamoeba Keratitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ketoconazole

Genetic Tests for Acanthamoeba Keratitis

Anatomical Context for Acanthamoeba Keratitis

MalaCards organs/tissues related to Acanthamoeba Keratitis:

41
Eye, Testes, Skin, Retina, Brain, Thymus, Cortex

Publications for Acanthamoeba Keratitis

Articles related to Acanthamoeba Keratitis:

(show top 50) (show all 1052)
# Title Authors PMID Year
1
High fluence PACK-CXL as adjuvant treatment for advanced Acanthamoeba keratitis. 38
31312750 2019
2
Early Penetrating Keratoplasty À Chaud May Improve Outcome in Therapy-Resistant Acanthamoeba Keratitis. 38
31317392 2019
3
Efficient therapeutic effect of Nigella sativa aqueous extract and chitosan nanoparticles against experimentally induced Acanthamoeba keratitis. 38
31144032 2019
4
[Diagnostic value of fungal fluorescence staining on corneal scrapings for fungal keratitis]. 38
31422639 2019
5
Reduction of Acanthamoeba Cyst Density Associated With Treatment Detected by In Vivo Confocal Microscopy in Acanthamoeba Keratitis. 38
31169613 2019
6
Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases. 38
31401556 2019
7
Synergy Testing of Antiamoebic Agents for Acanthamoeba: Antagonistic Effect of Voriconazole. 38
31306283 2019
8
Effectiveness of sampling methods employed for Acanthamoeba keratitis diagnosis by culture. 38
29916123 2019
9
Clinical features and serial changes of Acanthamoeba keratitis: an in vivo confocal microscopy study. 38
31292523 2019
10
Acanthamoeba Keratitis. 38
31314971 2019
11
Oral Miltefosine as Adjunctive Treatment for Recalcitrant Acanthamoeba Keratitis. 38
31170106 2019
12
Corneal Endotheliitis as a Presentation of Acanthamoeba Keratitis. 38
31219868 2019
13
Therapeutic penetrating keratoplasty for acanthamoeba keratitis: a review of cases, complications and predictive factors. 38
31214859 2019
14
Role of in vivo confocal microscopy in the diagnosis of infectious keratitis. 38
31209694 2019
15
Water Exposure and the Risk of Contact Lens-Related Disease. 38
30789440 2019
16
Synthesis and in vitro activity of new biguanide-containing dendrimers on pathogenic isolates of Acanthamoeba polyphaga and Acanthamoeba griffini. 38
31069536 2019
17
Cobalt nanoparticles as novel nanotherapeutics against Acanthamoeba castellanii. 38
31159839 2019
18
Torn from the headlines: role of public awareness and bench- to-bedside research in prevention and treatment of Acanthamoeba keratitis. 38
30552420 2019
19
Clinical features and outcomes of Acanthamoeba keratitis in a tertiary hospital over 20- year period. 38
31076316 2019
20
Efficacy of Topical Miltefosine in Patients with Acanthamoeba Keratitis: A Pilot Study. 38
30572075 2019
21
Notes from the Field: Acanthamoeba Keratitis Cases - Iowa, 2002-2017. 38
31095535 2019
22
[Infectious keratitis in contact lens wearers]. 38
31120209 2019
23
The Acanthamoeba-Fungal Keratitis Study. 38
30721687 2019
24
Reduction of Acanthamoeba Cyst Density Associated With Treatment Detected by In Vivo Confocal Microscopy in Acanthamoeba Keratitis. 38
30640249 2019
25
Analysis from a year of increased cases of Acanthamoeba Keratitis in a large teaching hospital in the UK. 38
31018907 2019
26
Tear Inflammatory Molecules in Contact Lens Wearers: A Literature Review. 38
30963963 2019
27
Evidence of human-like Ca2+ channels and effects of Ca2+ channel blockers in Acanthamoeba castellanii. 38
30362253 2019
28
Acanthamoeba keratitis - Clinical signs, differential diagnosis and treatment. 38
30899841 2019
29
Clinical course of Acanthamoeba keratitis by genotypes T4 and T8 in Hungary. 38
30835133 2019
30
Accelerated collagen cross-linking in the management of advanced Acanthamoeba keratitis. 38
30726402 2019
31
Drug targeting in Acanthamoeba keratitis: rational of using drugs that are already approved for ocular use in non-keratitis indications. 38
30356128 2019
32
Dual 0.02% chlorhexidine digluconate - 0.1% disodium EDTA loaded thermosensitive ocular gel for Acanthamoeba keratitis treatment. 38
30553004 2019
33
Genotypic diversity of Acanthamoeba strains isolated from Chilean patients with Acanthamoeba keratitis. 38
30683157 2019
34
Acanthamoeba keratitis in Mexico: Report of a clinical case and importance of sensitivity assays for a better outcome. 38
30472333 2019
35
Box Behnken design of siRNA-loaded liposomes for the treatment of a murine model of ocular keratitis caused by Acanthamoeba. 38
30384269 2019
36
Evaluation of in vitro effects of selected physical and chemical agents on detected in Poland Acanthamoeba strains – factors of increasing threats for public health 38
31095904 2019
37
Comparison of Proteins Secreted into Extracellular Space of Pathogenic and Non-pathogenic Acanthamoeba castellanii. 38
30630275 2018
38
Effect of povidone iodine, chlorhexidine digluconate and toyocamycin on amphizoic amoebic strains, infectious agents of <i>Acanthamoeba</i> keratitis - a growing threat to human health worldwide. 38
30586959 2018
39
Total necrosis of cornea, iris and crystalline lens with exposure of vitreous hyaloid face in the context of recalcitrant acanthamoeba keratitis. 38
30555975 2018
40
Acanthamoeba keratitis: confirmation of the UK outbreak and a prospective case-control study identifying contributing risk factors. 38
30232172 2018
41
Molecular Bioburden of the Lens Storage Case for Contact Lens-Related Keratitis. 38
30044251 2018
42
[Early Diagnosis and Successful Medical Treatment of Acanthamoeba Keratitis]. 38
29723885 2018
43
Pythium insidiosum and Acanthamoeba keratitis in a contact lens user. 38
30567163 2018
44
Corneal "Plaque" formation after anti-acanthamoeba therapy in acanthamoeba keratitis. 38
30355882 2018
45
Acanthamoeba Keratitis: Are Recent Cases More Severe? 38
29847494 2018
46
Tannic acid-modified silver nanoparticles as a novel therapeutic agent against Acanthamoeba. 38
30112674 2018
47
Molecular and biochemical characterization of key enzymes in the cysteine and serine metabolic pathways of Acanthamoeba castellanii. 38
30477573 2018
48
Intracorneal injection of a detachable hybrid microneedle for sustained drug delivery. 38
30267886 2018
49
A report of 10 patients with Acanthamoeba keratitis. 38
29885816 2018
50
Acanthamoeba keratitis in 194 patients: risk factors for bad outcomes and severe inflammatory complications. 38
29298778 2018

Variations for Acanthamoeba Keratitis

Expression for Acanthamoeba Keratitis

Search GEO for disease gene expression data for Acanthamoeba Keratitis.

Pathways for Acanthamoeba Keratitis

Pathways related to Acanthamoeba Keratitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.77 MBL2 F5

GO Terms for Acanthamoeba Keratitis

Cellular components related to Acanthamoeba Keratitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.26 MBL2 F5 CXCL2 APOH
2 extracellular space GO:0005615 8.92 MBL2 F5 CXCL2 APOH

Biological processes related to Acanthamoeba Keratitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 8.62 F5 APOH

Sources for Acanthamoeba Keratitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....